Transcriptome analysis of Lorecivivint-treated monocytic cells (THP-1) (KAP230662)
To identify biomarkers that change when treated with the DYRK1A and CLK2 inhibitor, Lorecivivint, compared to PBS. To do this, it inhibited an immune response by treating human monocytic THP-1 cells with LPS.